Dr. Gregory J. Moore Appointed to Denali Therapeutics & DaVita’s Board of Directors by Cellarity
June 25, 2023
🌥️Trending News
Cellarity recently announced the appointment of Dr. Gregory J. Moore to the Board of Directors of Denali Therapeutics ($NASDAQ:DNLI) and DaVita. Dr. Moore is an accomplished leader with extensive experience in biotechnology and healthcare in both industry and academia. Denali Therapeutics is a leading biotechnology company focused on developing and commercializing transformative therapies for patients with neurological and neurodegenerative diseases. The company has a portfolio of novel, differentiated therapies based on its proprietary platform and cutting-edge science, and is dedicated to unlocking treatments for these serious conditions.
The company has a number of ongoing clinical trials and has secured strategic partnerships with leading companies in the industry. The company provides comprehensive care for patients with kidney disease, including dialysis treatments, clinical laboratory services, transplantation support services, and pharmacy services. With his expertise in biotechnology, healthcare, and strategic partnerships, Dr. Moore will be a valuable asset to the companies as they continue their quest to develop innovative treatments for patients with neurological and neurodegenerative diseases.
Stock Price
Dr. Moore brings extensive experience in the fields of healthcare, biotechnology, biopharmaceuticals and venture capital to the position. This news was met with positive sentiment in the markets, with DENALI THERAPEUTICS stock opening at $30.6 and closing at $30.8, up 0.7% from its previous closing price of $30.6. This increase demonstrates the investors’ faith in Dr. Moore’s ability to help drive growth and further strengthen the performance of Denali Therapeutics and DaVita. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Denali Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 101.46 | -370.55 | -365.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Denali Therapeutics. More…
| Operations | Investing | Financing |
| -231.41 | -116.22 | 310.81 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Denali Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.41k | 442.64 | 7.07 |
Key Ratios Snapshot
Some of the financial key ratios for Denali Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 57.3% | – | -389.4% |
| FCF Margin | ROE | ROA |
| -244.4% | -24.6% | -17.5% |
Analysis
At GoodWhale, we have taken an in-depth look into the financials of DENALI THERAPEUTICS and have come to the conclusion that it is a medium risk investment. After careful consideration, our Risk Rating system has flagged three potential risk warnings within the income sheet, balance sheet, and cashflow statement. To gain access to the full details of this analysis, you must become a registered user with GoodWhale. More…
Peers
The biotech sector is full of companies vying for market share andDenali Therapeutics Inc is no different. It competes againstG1 Therapeutics Inc, Kezar Life Sciences Inc, and Ryvu Therapeutics SA, among others.
– G1 Therapeutics Inc ($NASDAQ:GTHX)
G1 Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics for the treatment of cancer. The company’s lead product candidate is trilaciclib, which is in Phase III clinical trials for the treatment of small cell lung cancer. G1 Therapeutics Inc has a market cap of 486.46M as of 2022 and a Return on Equity of -117.43%.
– Kezar Life Sciences Inc ($NASDAQ:KZR)
Kezar Life Sciences Inc is a clinical-stage biotechnology company that focuses on the discovery, development, and commercialization of novel small molecule therapeutics to treat autoimmune and other inflammatory diseases. The company has a market cap of 506.62M as of 2022 and a Return on Equity of -14.21%. Kezar Life Sciences Inc is headquartered in South San Francisco, California.
– Ryvu Therapeutics SA ($LTS:0RKT)
Ryu Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of serious and life-threatening diseases. The company’s lead product candidate, RT-001, is a first-in-class, investigational gene therapy for the treatment of patients with wet age-related macular degeneration. The company is also developing RT-002, a gene therapy for the treatment of patients with X-linked retinitis pigmentosa, and RT-003, a gene therapy for the treatment of patients with Usher syndrome type 1c.
Summary
Denali Therapeutics is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases. Recently, the company has appointed Dr. Gregory J. Moore to its board of directors. This is a positive move, as Moore brings extensive experience in the fields of finance and venture capital, as well as his knowledge in the biotechnology industry.
Analysts believe that Moore’s experience and expertise will be beneficial in helping Denali to identify new investing opportunities, strengthen their financial position, and increase their competitiveness in the market. His appointment should be taken as a sign of Denali’s commitment to developing treatments that will improve the lives of those affected by neurodegenerative diseases.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
